First human-sized, living disc replacements derived from proprietary discogenic progenitor cells mark milestone in regenerative spine medicine
Peer-Reviewed Article Reporting DiscGenics’ Cell Therapy Phase I/II Study Results Receives International Journal of Spine Surgery Best Paper Award
DiscGenics Announces US FDA Approval to Proceed with Phase III Clinical Evaluation of Allogeneic, Injectable Disc Progenitor Cell Therapy for Symptomatic Lumbar Degenerative Disc Disease
DiscGenics has gained acceptance from the U.S. FDA for the clinical protocols and Chemistry, Manufacturing, and Controls (CMC) clinical development plan for Phase III clinical program of its allogeneic, injectable disc progenitor cell therapy (IDCT or rebonuputemcel) for painful lumbar degenerative disc disease (DDD), allowing the study to proceed.
The International Journal of Spine Surgery Has Published Results from an FDA-Approved Study of an Allogeneic Disc Progenitor Cell Therapy for the Treatment of Adults with Lumbar Disc Degeneration
The International Journal of Spine Surgery publishes results from the combined Phase I/Phase II, first-in-human clinical study of an allogeneic disc progenitor cell therapy (IDCT or rebonuputemcel) for painful lumbar degenerative disc disease.
DiscGenics to Present at Canaccord Genuity 2024 Musculoskeletal Conference
DiscGenics to Present at Biotech Showcase 2024
DiscGenics Announces Research Collaboration with the U.S. Department of Veterans Affairs for Tissue-Engineered Discs with Discogenic Cells
DiscGenics has announced a basic science Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Veterans Affairs (VA) to assess the feasibility of using DiscGenics’ proprietary Discogenic Cells with the VA’s whole, tissue-engineered endplate-modified disc-like angle ply structure (eDAPS).
DiscGenics CEO to Present at Upcoming Industry Conferences
Salt Lake City, UT – September 26, 2023 – DiscGenics, Inc., a privately held, late-stage clinical, biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that Flagg Flanagan, Chief Executive Officer and Chairman of DiscGenics will present at the following conferences:
East-West BioPharma Summit being held October 2-4 in Cambridge, Massachusetts and livestreamed globally.
Format Company Presentation
Date: Wednesday, October 4, 2023
Time: 9:45 AM ET
Location: Salon 5-6 at the Boston Marriott Cambridge
Organized by BioCentury and BayHelix in collaboration with McKinsey & Company, the East-West BioPharma Summit brings together industry leaders and investors to debate global development strategy, and to network with peers from both the East and West.
Virtual attendance is available, which includes access to a recording of DiscGenics’ company presentation. For more information, please visit: https://conferences.biocentury.com/east-west-summit.
2023 Cell & Gene Meeting on the Mesa being held October 10-12 in Carlsbad, California and livestreamed globally.
Format Company Presentation
Date: Tuesday, October 10, 2023
Time: 9:45 AM PT
Location: Ecolab Life Sciences Ballroom at the Park Hyatt Aviara Resort
Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a three-day conference featuring more than 120 dedicated company presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies, as well as over 100 panelists and featured speakers.
Virtual attendance is available, which includes a livestream of DiscGenics’ presentation and the ability to view all conference sessions on-demand. For more information, please visit https://meetingonthemesa.com.
About DiscGenics
DiscGenics is a privately held, late-stage clinical, biopharmaceutical company developing cell-based regenerative therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. DiscGenics’s first product candidate, IDCT (rebonuputemcel), is an allogeneic, injectable discogenic progenitor cell therapy for symptomatic, mild to moderate lumbar disc degeneration. IDCT is a mixture of live Discogenic Cells, which are a manufactured progenitor cell population derived from donated adult human intervertebral disc tissue, and a viscous carrier. IDCT has been granted regenerative medicine advanced therapy (RMAT) and Fast Track designations by the U.S. Food and Drug Administration. As the only company in the world to develop an allogeneic cell therapy derived from intervertebral disc cells to treat diseases of the disc, DiscGenics has a unique opportunity to offer a non-surgical, potentially regenerative solution for the treatment of patients suffering from the debilitating effects of back pain.
DiscGenics to Present at Canaccord Genuity’s 2023 Musculoskeletal Conference
DiscGenics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to IDCT for Degenerative Disc Disease
DiscGenics Announces Positive Two-Year Clinical Data from Study of Discogenic Progenitor Cell Therapy for Degenerative Disc Disease
DiscGenics to Present at 41st Annual J.P. Morgan Healthcare Conference
Two-Year Clinical Data for DiscGenics’s Progenitor Cell Therapy for Lumbar Disc Degeneration to Be Presented at NASS 2022
DiscGenics to Present at 2022 Cell and Gene Meeting on the Mesa
DiscGenics Announces Presentation of Positive Interim Clinical Data from Phase 1/2 Study of Cell Therapy for Degenerative Disc Disease
IDCT was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection; improvements were sustained at the one-year interim readout with additional data to follow at 18 and 24 months.
